Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
ANI Pharmaceuticals ( (ANIP) ) has provided an update.
ANI Pharmaceuticals announced its preliminary financial results for 2024 and outlook for 2025, affirming its net revenues and earnings guidance for 2024 and projecting significant growth in 2025. The company reported strong performance in its Rare Disease segment following the acquisition of Alimera, with expectations of continued robust growth driven by this franchise. The preliminary 2025 financial targets reflect a projected revenue growth of 24% to 27%, indicating a positive outlook for stakeholders.
More about ANI Pharmaceuticals
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing innovative therapeutics. The company aims for sustainable growth through its Rare Disease business, which markets products in ophthalmology, rheumatology, nephrology, neurology, and pulmonology, alongside its Generics and Established Brands businesses.
YTD Price Performance: -0.72%
Average Trading Volume: 254,537
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $1.16B
See more insights into ANIP stock on TipRanks’ Stock Analysis page.
